The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Imatinib-related interstitial lung disease.
British journal of haematology 2018 03;180;780 — 2018 03 — 780
Acute pulmonary complications in patients with hematologic malignancies.
Radiographics : a review publication of the Radiological Society of North America, Inc 2014 Oct;34;1755-68 — 2014 Oct — 1755-68
Interstitial pneumonitis in a patient with chronic myeloid leukemia.
Turkish journal of haematology : official journal of Turkish Society of Haematology 2013 Dec;30;435-6 — 2013 Dec — 435-6
Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.
International journal of hematology 2013 Feb;97;299-300 — 2013 Feb — 299-300
Nakashima S, Kakugawa T, Motomura H, Hirano K, Sasaki E, Nagata Y, Kinoshita A, Sakamoto N, Ishimatsu Y, Mukae H, Kohno S
Development of imatinibmesylate-induced interstitial lung disease 2?weeks after discontinuation of the treatment: a case report.
Multidisciplinary respiratory medicine 2012 Nov 23;7;48 — 2012 Nov 23 — 48
Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.
Leukemia & lymphoma 2012 Feb;53;332-3 — 2012 Feb — 332-3
[A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
Terapevticheskii arkhiv 2010;82;59-61 — 2010 — 59-61
[Imatinib-induced pulmonary toxicity].
Gaceta medica de Mexico 2009 Sep-Oct;145;437-9 — 2009 Sep-Oct — 437-9
Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.
Leukemia 2006 Jun;20;1162-4 — 2006 Jun — 1162-4
Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.
Respiration; international review of thoracic diseases 2008;75;350-4 — 2008 — 350-4
Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
American journal of hematology 2005 May;79;80-1 — 2005 May — 80-1
Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms.
Internal medicine journal 2005 Feb;35;136-7 — 2005 Feb — 136-7
Imatinib mesylate-induced interstitial pneumonitis.
Mayo Clinic proceedings 2003 Dec;78;1578-9 — 2003 Dec — 1578-9
Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Aug 15;21;3171-3 — 2003 Aug 15 — 3171-3
Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Espérou H, Socié G, Calvo F, Gluckman E, Ribaud P, Rousselot P, Tazi A
Hypersensitivity pneumonitis related to imatinib mesylate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Oct 15;20;4271-2 — 2002 Oct 15 — 4271-2